Introduction
============

About a century ago, Alois Alzheimer and Emil Kraepelin described the historical equivalents of AD and BIP ([@B5]; [@B65]). Still their etiologies are incompletely understood and no curative treatments exist ([@B39]; [@B105]). The Global Burden of Disease study ranks AD and BIP among the top thirty causes of years lived with disability worldwide ([@B115]).

Alzheimer's disease is a neurodegenerative disorder ([@B50]) usually presenting in late adult life ([@B62]), while BIP is considered a neurodevelopmental disorder ([@B103]; [@B92]) with average age at onset in early adult life ([@B12]). Yet, epidemiological, pathophysiological, and clinical data suggest that AD and BIP could be related. A recent meta-analysis reports an odds ratio of 2.4 (95% CI 1.4--4.1) for dementia of all causes among patients with BIP ([@B26]). The risk of dementia is higher among patients with BIP compared to patients with arthritis, diabetes, and schizophrenia ([@B58]; [@B57]). Among patients with BIP, treatment with lithium is associated with a reduced risk of dementia ([@B56]; [@B35]) and AD ([@B89]) in most, but not all ([@B15]), observational studies. Among patients with AD or mild cognitive impairment, a meta-analysis of randomized controlled studies found that lithium decreased cognitive decline ([@B81]). Shared pathophysiological processes between AD and BIP are reported in the kynurenine pathway ([@B85]; [@B87]; [@B97]; [@B43]; [@B77]; [@B104]). There is also evidence of inflammatory processes in both conditions ([@B38]; [@B10]; [@B46]). Further, euthymic patients with BIP have impairments of episodic memory ([@B112]) and executive dysfunction ([@B112]; [@B79]), which are also core symptoms of AD ([@B37]; [@B36]).

Despite several lines of evidence suggesting a relation between AD and BIP, it is not established if the conditions have a shared genetic basis. AD and BIP are in most cases complex traits, i.e., they are influenced by several genetic and environmental factors. Twin studies estimate the heritability of AD and BIP to 60% or higher ([@B83]; [@B59]; [@B34]; [@B72]). Genome wide association studies (GWASs) are the gold standard for hypothesis-free assessment of associations between complex traits and common genetic variants ([@B18]). The common variants refer to single nucleotide polymorphisms (SNPs) with minor allele frequencies \> 1--5%. The power of a GWAS is a function of study sample size and the genetic architecture of the trait (i.e., the narrow-sense heritability, the number of causal variants, their effect sizes, and population frequencies) ([@B106]; [@B32]). AD and BIP are considered highly polygenic ([@B96]; [@B30]), and ∼1/3 of their heritability can be explained by SNPs with tiny effect sizes that are not individually detectable given the power of current GWASs ([@B69], [@B68]; [@B102], [@B101]).

With the current sample sizes, however, the power of GWASs can be boosted by leveraging polygenic overlap between complex traits ([@B8],[@B9], [@B7]). Shared genetic influences are common among complex traits ([@B114]). Statistical methods based on the conditional FDR framework can detect polygenic overlap between complex traits and utilize this polygenic overlap to increase the power to identify common genetic variants associated with each trait and jointly with two or more traits ([@B8],[@B9], [@B7]). We aimed to use these methods to identify the shared genetic basis between AD and BIP.

Materials and Methods {#s1}
=====================

Data Sources
------------

We obtained summary statistics (i.e., effect sizes and corresponding *p*-values for all SNPs) from the IGAP ([@B67]) and the PGC2-BIP ([@B110]).

### International Genomics of Alzheimer's Project

The IGAP is a two-stage study. We used data from stage 1 of the study, which is based upon four previously published GWASs \[The European Alzheimer's Disease Initiative ([@B28]; [@B45]), the Alzheimer Disease Genetics Consortium ([@B54]), The Cohorts for Heart and Aging Research in Genomic Epidemiology consortium ([@B95]), The Genetic and Environmental Risk in AD consortium ([@B44])\] on 17,008 AD cases and 37,154 controls of European ancestry. The IMPUTE2 ([@B48]) or MaCH/Minimac ([@B71]) software were used to impute SNPs from the European ancestry haplotypes in the 1000 Genome Project ([@B3]). In stage 2 of the study, SNPs with *p*-values \< 1 × 10^-3^ from stage 1 were selected for genotyping in independent samples. We did not use data from stage 2 of the study since the conditional FDR method require genome-wide summary statistics which are not inflated.

Diagnoses of AD in the sub-studies of IGAP were in most cases made clinically according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association criteria ([@B84]) or the Diagnostic and Statistical Manual of Mental Disorders ([@B6]) criteria, or post mortem according to the National Institute of Ageing-Regan criteria ([@B88]).

Informed consents were provided from all participants, or, in the case of substantial cognitive impairment, from caregivers, legal guardians, or other proxies. The sub-studies were approved by local ethic committees.

For further details, we refer to the original publication ([@B67]).

### Psychiatric Genetic Consortium 2 Bipolar Disorder Working Group

The PGC2-BIP is a GWAS based upon 32 sub-studies on 20,352 BIP cases and 31,358 controls of European ancestry. Arrays for genotyping were chosen by each sub-study. The *Ricopoli* pipeline^[1](#fn01){ref-type="fn"}^ was used to standardize quality control, imputation, and analyses of genotypic data from all samples except one. SNPs were excluded by the following criteria: missingness in \> 5 (before sample removal) or 2% (after sample removal), *p*-value for Hardy--Weinberg equilibrium \< 1 × 10^-10^ in cases or \<1 × 10^-6^ in controls, missingness difference between cases and controls \> 2%, or autosomal heterozygosity deviation (\|*F~het~*\| \> 0.2). Individuals with \> 2% missing genotypes were also excluded. The IMPUTE2 ([@B48]) and SHAPEIT2 ([@B23]) software were used for imputation.

Diagnoses of BIP were established by clinical interviews or obtained from hospital record data according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition ([@B6]), the International Classification of Diseases 9th revision ([@B119]), or the International Classification of Diseases 10th revision ([@B120]).

Informed consents were provided from all participants. The sub-studies were approved by local ethical committees.

For further details, we refer to the original publication ([@B110]).

### Data Availability

Data from the IGAP^[2](#fn02){ref-type="fn"}^ and PGC2-BIP^[3](#fn03){ref-type="fn"}^ studies are publicly available for download.

Statistical Analyses
--------------------

### Conditional Quantile--Quantile (QQ)-Plots

We used conditional QQ-plots to visually assess pleiotropic enrichment. A conditional QQ-plot displays the distribution of p-values for the first trait, e.g., AD, conditioned on association levels for the second trait, e.g., BIP. Pleiotropic enrichment is present if the degree of leftward shift from the expected null line for the first trait is dependent on the degree of association with the second trait. For further details, we refer to previous studies ([@B8],[@B9], [@B7]) and Supplementary Methods [1.1](#SM1){ref-type="supplementary-material"}.

### Conditional False Discovery Rate (condFDR)

The enrichment observed in conditional QQ-plots can be translated to FDR for each SNP. We used the conditional false discovery rate (condFDR) to improve power to detect SNPs associated with AD given associations with BIP and *vice versa*. condFDR is defined as "the posterior probability that a given SNP is null for the first trait given that the p-values for both traits are as small or smaller than the observed *p*-values" ([@B7]). We denoted condFDR for AD given associations with BIP as condFDR~(ADjBIP)~ and for BIP given association with AD as condFDR~(BIPj~ ~AD)~ and considered values \< 0.01 significant. For further details, we refer to previous studies ([@B8],[@B9], [@B7]) and Supplementary Methods [1.2](#SM1){ref-type="supplementary-material"}.

### Conjunctional False Discovery Rate (conjFDR)

We used conjunctional FDR (conjFDR) to identify SNPs jointly associated with AD and BIP. conjFDR is defined as "the posterior probability that a SNP is null for either phenotype or both simultaneously, given the *p*-values for both traits are as small or smaller than the observed *p*-values" ([@B7]). After repeating the condFDR procedure for both traits, we identified shared loci at conjFDR \< 0.05, which is given by the maximum between the condFDRs for both traits. Hence, the conjFDR analysis is a conservative approach requiring that loci exceed a condFDR significance threshold for two traits simultaneously. For further details, we refer to previous studies ([@B8],[@B9], [@B7]) and Supplementary Methods [1.3](#SM1){ref-type="supplementary-material"}.

### Conditional and Conjunctional Manhattan Plots

We constructed conditional Manhattan plots to visualize the chromosomal location of SNPs with condFDR~(ADjBIP)~ ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}) and condFDR~(BIPjAD)~ \< 0.01 ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}). We constructed a similar plot for SNPs jointly associated with AD and BIP at a conjFDR \< 0.05 ([Figure 2](#F2){ref-type="fig"}).

### Assessment of Novelty

To determine if a locus was novel, we first checked that the p-value(s) for the implicating variant was \> 5 × 10^-8^ in the original GWAS(s). Further, we used LDlink ([@B74]) to exclude variants which are in LD (*r*^2^\> 0.1) with any of the genome-wide significant hits in the original GWAS(s). Finally, we conducted a search on PubMed using the term ("SNP id" OR "gene name") AND ("Bipolar Disorder"\[Mesh\] OR "Alzheimer Disease"\[Mesh\]) to exclude that the variants or implicated genes have been associated with AD or BIP at genome-wide significance in previous GWASs.

### Cerebral Gene Expression Across Lifespan of the Implicated Loci

The Human Brain Transcriptome (HBT) project^[4](#fn04){ref-type="fn"}^ used postmortem brain tissue from over 1,340 samples to provide genome-wide exon-level transcriptome data in 16 cerebral regions ([@B55]). We obtained figures from the HBT project on gene expression in different cerebral areas as a function of age (i.e., from embryonic life through late adulthood) for the nearest genes to the loci jointly associated with AD and BIP.

### Control of Spurious Enrichment

We randomly chose one SNP in each LD block (*r*^2^\> 0.1), and calculated the average empirical cumulative distribution function (ecdf) by using the *p*-values obtained through 200 iterations. SNPs within the major histocompatibility complex region (defined as chr6:25652429--33368333) and the apolipoprotein E (*APOE*) gene (chr19:44909039--45912650), and SNPs in LD (*r*^2^\> 0.1) with these SNPs, were excluded from the analyses due to their complex LD structure ([@B22]) and known association to AD ([@B66]; [@B105]), which could bias the estimates of enrichment. Further, we used LD-independent (*r*^2^\< 0.1) intergenic SNPs, which are depleted of true associations, to calculate an inflation factor value ([@B117]). We divided all test statistics on this value to control for genomic inflation.

### Cross-Trait Linkage Disequilibrium Score Regression (LDSR)

We calculated the degree of genetic correlation between AD and BIP using cross-trait LD score regression (LDSR) ([@B14]). For details, we refer to Supplementary Materials [1.4](#SM1){ref-type="supplementary-material"}.

Ethics Statement
----------------

All GWASs performed and investigated in the present study were approved by the local ethics committees, and informed consent was obtained from all participants. Furthermore, the Norwegian Institutional Review Board for the South-East Norway Region has evaluated the methods used in the current study and found that no additional institutional review board approval was needed because no individual data were used (ref. 2011/1980).

Results
=======

Pleiotropic Enrichment
----------------------

In the conditional QQ-plots, we observed enrichment of associations with AD given increasing SNP associations with BIP, and *vice versa* ([Figure 1](#F1){ref-type="fig"}). These findings indicate polygenic overlap between AD and BIP across common genetic variants.

![Conditional QQ-plots of nominal p-values at y-axis and 1 - empirical cumulative distribution function on *x*-axis for **(A)** Alzheimer's disease (AD) with lines representing strata of SNPs according to their degree of association with bipolar disorder (BIP) and **(B)** BIP with lines representing strata of SNPs according to their degree of association with AD.](fnins-13-00220-g001){#F1}

Improving Genetic Discovery Using Conditional FDR
-------------------------------------------------

We then leveraged the pleiotropic enrichment observed in conditional QQ-plots to boost SNP discovery in both traits using condFDR.

We identified 22 SNPs clumped into 19 independent loci at condFDR~(ADjBIP)~ \< 0.01 ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). The chromosomal locations of the nearest genes are visualized in a conditional Manhattan plot ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). Red annotations represent the four loci with a lower conditional than unconditional FDR. Of these four loci, two loci have uncorrected *p*-values \> 5 × 10^-8^ in the original GWAS and are thus not identified by traditional methods; *NDUFS3* (rs71475924, intron variant) and *MTSS1L* (rs12597717, intron variant). The signal in *NDUFS3* was driven by one single SNP and is thus probably a spurious association.

Further, we identified 24 SNPs within 24 loci at a condFDR~(BIPjAD)~ \< 0.01 ([Supplementary Table 2](#SM1){ref-type="supplementary-material"}). As visualized in the conditional Manhatton plot ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}), 17 loci had a lower conditional than unconditional FDR. Of these 17 loci, 10 variants have uncorrected *p*-values \> 5 × 10^-8^ in the original GWAS and are thus not identified by traditional methods; *LOC105378763* (rs1889778, intron variant), *CNTNAP5* (rs13011184, intron variant), *KIAA1109* (rs45605540, intron variant), *SSBP2* (rs7707981, intron variant), *AK091365* (rs2388334, no genic locational annotation), *RCOR2* (rs4980532, intron variant), *STARD9* (rs4447398, intron variant), *GRIN2A* (rs11647445, intron variant), *THRA* (rs61554907, intron variant), and *PRKCA* (rs7406066, intron variant). However; the *CNTNAP5* gene has previously been associated with the posterior cortical atrophy variant of AD at genome-wide significance ([@B107]) and with BIP ([@B27]).

Identification of Shared Loci
-----------------------------

Finally, we applied conjFDR to assess for SNPs jointly associated with AD and BIP. We used effect sizes from the original data sources to determine the allelic direction of effects in both traits.

We identified two SNPs at two loci at a conjFDR~(AD&BIP)~ \< 0.05 ([Table 1](#T1){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). A 2 kb upstream variant at *MARK2* (rs10792421) was associated with AD and BIP with the same direction of effect on AD and BIP \[conjFDR~(AD&BIP)~ = 0.030, *z*-score~(AD)~ = 3.99, *z*-score~(BIP)~ = 4.74\]. *MARK2* is widely expressed in the developing and adult human brain ([Supplementary Figure 3](#SM1){ref-type="supplementary-material"}). An intronic variant within *VAC14* (rs11649476) was associated with AD and BIP with opposite directions of effect in AD and BIP \[conjFDR~(AD&BIP)~ = 0.022, *z*-score~(AD)~ = -4.35, *z*-score~(BIP)~ = 4.18\]. *VAC14* is also widely expressed in the developing and adult human brain ([Supplementary Figure 4](#SM1){ref-type="supplementary-material"}). Both SNPs have *p*-values \> 5 × 10^-8^ for both traits in the original GWASs and are thus not identified by traditional methods.

###### 

SNPs with related genes jointly associated with Alzheimer's disease (AD) and bipolar disorder (BIP) at a conjunctional false discovery rate (conjFDR(~AD&BIP)~) \< 0.05.

  SNP          Chr. region   Position   Closest gene   Location relative to the closest gene   *P*-value~(AD)~   *P*-value~(BIP)~   conjFDR~(AD&BIP)~   Effective/ other allele   Direction of effect in AD/BIP
  ------------ ------------- ---------- -------------- --------------------------------------- ----------------- ------------------ ------------------- ------------------------- -------------------------------
  rs10792421   11q13.1       63605177   MARK2          Upstream                                6.68E-05          2.16E-05           3.02E-02            G/A                       +/+
  rs11649476   16q22.2       70736752   VAC14          Intronic                                1.35E-05          2.98E-05           2.18E-02            T/C                       -/+
                                                                                                                                                                                  

![Conjunctional Manhatton plot of loci jointly associated with Alzheimer's disease (AD) and bipolar disorder (BIP) at a conjuntional false discovery rate \< 0.05.](fnins-13-00220-g002){#F2}

Genetic Correlation
-------------------

We estimated that there is no overall genetic correlation between AD and BIP according to LDSR (*r*~g~ = -0.0222, *SE* = 0.0519, *p* = 0.669).

Discussion
==========

We used statistical methods based on the condFDR framework and showed that AD and BIP have a shared genetic basis. Our study adds new insights into the relation between AD and BIP by finding polygenic overlap, one novel locus associated with AD and nine novel loci associated with BIP when conditioned on associations with the other trait, and two novel loci jointly associated with both traits.

A polygenic overlap between AD and BIP could implicate shared genetic influences as a part of the explanation to the epidemiological ([@B26]), pathophysiological ([@B38]; [@B46]), and clinical ([@B37]; [@B79]; [@B36]) links between the diseases. However, we do not find an overall genetic correlation as assessed with cross-trait LDSR ([@B14]). Also, one of the two jointly associated SNPs demonstrates effects in opposite directions. These findings are compatible with a scenario where the polygenic overlap between AD and BIP involves a mixed direction of effects of the implicated SNPs yielding no genome-wide correlation ([@B32]). Thus, absence of an overall genetic correlation between brain disorders, as evident for several traits (including AD and BIP) in the study of [@B11], does not imply lack of genetic overlap.

The loci implicating the *MARK2* and *VAC14* genes were jointly associated with AD and BIP ([Table 1](#T1){ref-type="table"}). Both genes are widely expressed in the human brain throughout life ([Supplementary Figures 3](#SM1){ref-type="supplementary-material"}, [4](#SM1){ref-type="supplementary-material"}), which implies a spatial and temporal relation to both neurodevelopmental and neurodegenerative processes. The locus implicating the *MARK2* gene (rs10792421) had a concordant direction of effect in both traits ([Table 1](#T1){ref-type="table"}). The *MARK2* gene encodes the microtubule affinity regulating kinase 2 (MARK2). The kinase is involved in a diversity of neuronal cellular processes, including neuronal migration, and tau phosphorylation ([@B80]). Migration of immature neurons is necessary for corticogenesis ([@B63]). BIP is considered a neurodevelopmental disorder partly because of previous findings of cortical cell migration abnormalities ([@B103]; [@B92]). Abnormal neuronal migration might also be involved in later stages of life among patients with AD ([@B99]). Tauopathy is one of the pathophysiological hallmarks of AD ([@B50]). [@B40] demonstrated that MARK2 increases the phosphorylation of tau *in situ* and found interactions between MARK2 and tau in postmortem human AD brain tissue. The role of tauopathy has also been explored in BIP. A study of cerebrospinal fluid among younger patients with BIP ([@B52]) and a similar study of elderly patients with BIP and mild cognitive impairment ([@B31]) did not find any evidence of tauopathy. However, in another study, the total to phosphorylated tau ratio was reduced among patients with BIP carrying the risk allele of a common variant related to the previously discovered BIP risk gene *CACNA1C* ([@B51]). A similar reduction was not found among healthy controls carrying the same risk allele. These findings suggest an alteration in the regulation of tau phosphorylation in carriers of the risk allele that is restricted to patients with BIP. Further studies should explore whether interactions with other genes involved in regulation of tau phosphorylation, like the *MARK2* gene, could explain the specificity of the finding to patients with BIP. Lithium has several molecular targets including inhibition of glycogen synthase kinase 3β ([@B33]). Evidence is conflicting on whether glycogen synthase kinase 3β in turn inhibits or activates MARK2 ([@B64]; [@B111]). Consequently, it is unknown whether treatment with lithium could result in reduced or increased phosphorylation of tau among carriers of the common variant related to the *MARK2* gene.

The intronic variant within *VAC14* (rs11649476) was related to AD and BIP with opposite directions of effects. The same variant was shared between BIP and intelligence with concordant direction of effects in a recent study using conjunctional FDR ([@B108]). *VAC14* encodes a part of the PIKfyve protein kinase complex, which phosphorylates phosphatidylinositol 3-phosphate \[PI(3)P\] to phosphatidylinositol 3,5-bisphosphate \[PI(3,5)P~2~\] ([@B82]). PI(3,5)P~2~ is involved in endosomal homeostasis ([@B24]). A null mutation of *VAC14* in a mouse model resulted in perinatal death and massive neurodegeneration with vacuolated neurons ([@B125]). Amyloid precursor protein (APP) is a transmembrane protein involved in the pathophysiology of AD ([@B90]). [@B13] found that APP interacts with the PIKfyve complex to maintain endosomal homeostasis in *C. elegans*. They postulated that aberrant processing of APP contributes to the pathophysiology of AD through a cascade of reduced activation of PIKfyve, reduced levels of PI(3,5)P~2~, endosomal dysfunction, and reduced clearance of beta amyloid. Another example of the relationship between the processing of phosphoinositides and APP comes from a study of [@B86]. They found that inhibition of Vps34, a kinase phosphorylating phosphatidylinositol (PI) to PI(3)P, causes endolysosomal dysfunction with secretion of exosomes containing APP C-terminal fragments. [@B61] recently reported that serum levels of PI, the precursor of phosphoinositides like PI(3)P and PI(3,5)P~2~, is negatively associated with a proxy of genetic susceptibility to BIP.

Some of the genes implicated by the novel loci identified by conditional FDR analyses ([Supplementary Tables 1](#SM1){ref-type="supplementary-material"}, [2](#SM1){ref-type="supplementary-material"} and [Supplementary Figures 1](#SM1){ref-type="supplementary-material"}, [2](#SM1){ref-type="supplementary-material"}) also relate to known pathophysiological and clinical features of AD and BIP. The *PRKCA* gene encodes the protein kinase C alpha (PKCa). PKCa is described in amyloid plaque of patients with AD ([@B16]) where it could contribute to reduced synaptic activity ([@B2]). The *PRKCA* gene is higher expressed in bipolar mania compared to unipolar depression ([@B116]), and is lower expressed in fibroblasts of patients with BIP treated with lithium compared to those treated with other medications ([@B60]). Common genetic variants implicating the *PRKCA* gene are in healthy individuals associated to impairment of episodic memory ([@B75]). Variants within the *KIAA1109* gene are in family studies associated with multi-system syndromes characterized by impaired neurodevelopment ([@B1]; [@B42]), while the *MTSS1L* gene is associated with neurodegeneration in a consanguineous family study ([@B1]). The *STARD9* gene is necessary for spindle assembly during cell division in human development, and a mutation in the gene might cause a syndrome with intellectual disability ([@B91]). The locus implicating the *AK091365* gene was previously associated with general cognitive function when conditioned on association with schizophrenia ([@B109]), which in turn has a high genetic correlation with BIP ([@B14]). The *SSBP2* gene encodes the single strand DNA binding protein 2, which protects telomeres in a mouse model ([@B41]). In a Mendelian randomization study, [@B124] found that telomere length is causally related to AD. Telomere length is probably not reduced in most patients with BIP ([@B17]; [@B21]), however; one study found that patients with BIP treated with lithium had longer telomeres compared to patients not receiving lithium ([@B94]). The *RCOR2* gene product is related to cortical development ([@B118]) and inflammation ([@B4]) in mice. The *GRIN2A* gene encodes the GluN2A subunit of the *N-*methyl-D-aspartate (NMDA) receptor. The NMDA receptor is central for synaptic plasticity and learning ([@B70]). Memantine, an NMDA receptor antagonist, probably reduces cognitive decline ([@B100]; [@B47]) and neuropsychiatric symptoms ([@B78]) in AD. Ketamine, another NMDA receptor antagonist, can give short term remission of depression in BIP when used as an add-on to mood stabilizers ([@B25]; [@B123]). Mutations in *GRIN2A* are previously associated with a range of neuropsychiatric phenotypes including mental retardation, epilepsy, schizophrenia, and BIP ([@B49]; [@B122]).

Some of the genes implicated both at genome-wide significance in previously GWASs and by conditional FDR in the present study also have pathophysiological and clinical plausibility. The expression of *TRANK1* is decreased in induced pluripotent stem cells derived neurons carrying the common variant found in our study (rs9834970). Decreased expression of *TRANK1* alters the expression of other genes related to neuronal development and differentiation ([@B53]). Chronic treatment with sodium valproate, a mood stabilizer used in BIP ([@B76]), normalizes the expression of *TRANK1* ([@B53]). The *CNTNAP5* gene encodes a transmembrane protein of the neurexin family, which is related to cellular adhesion and intercellular communication ([@B113]). Common variants implicating *CNTNAP5* have previously been associated with the posterior cortical atrophy variant of AD ([@B107]), BIP ([@B27]), and response to antipsychotic treatment in schizophrenia ([@B121]), while rare variants within *CNTNAP5* have previously been associated with autism spectrum disorders ([@B93]). The *NCAN* gene is involved in neuronal adhesion and migration ([@B98]). Common variants implicating *NCAN* are associated with cognitive performance ([@B98]) and limbic gray matter volumes ([@B20]) in healthy individuals, while a rare variant is associated with dyslexia ([@B29]).

Further experimental studies should examine the implications of our findings. It is unknown if the loci implicated by condFDR and conjFDR relate to altered levels of gene expression, pathophysiological processes (e.g., impaired neuronal migration, tauopathy, and disturbed endosomal homeostasis), clinical features (e.g., cognitive and affective symptoms), and treatment response to lithium among patients with AD and BIP. Further, it is unknown if the loci interact with environmental risk factors and other genes implicated in AD and BIP.

Our results should be interpreted in light of the following limitations. We can neither exclude that some of the patients with AD have had BIP, nor that some of the patients with BIP will develop AD, which could have confounded our results. However; this could not explain the finding in the conjunctional FDR analyses of one locus implicated in AD and BIP with opposite directions of effect. Due to linkage disequilibrium among SNPs, our findings do not necessarily reflect causal variants, or that the same causal variants are involved in both traits. Although we found indications of modest polygenic overlap using conditional QQ-plots ([Figure 1](#F1){ref-type="fig"}), we only detected two genetic loci jointly associated with both AD and BIP ([Figure 2](#F2){ref-type="fig"}). However, the observed enrichment suggests that more shared SNPs will be identified when GWAS sample sizes increase ([@B106]). Further, we have only assessed the shared common genetic variants between AD and BIP. Other genetic variations, like rare structural variants, are also shown to increase the risk of AD and BIP ([@B73]; [@B19]). Lastly, most participants in the data used in our study are of European ancestry. The generalizability of our findings to samples dominated by participants of other ancestries is unknown.

Conclusion
==========

We find polygenic overlap between AD and BIP and identify novel loci associated with each trait and jointly with both traits, providing new insights into their genetic architecture. The genes *MARK2* and *VAC14* jointly implicated in AD and BIP are previously described to be involved in neuronal migration, tau phosphorylation, and endosomal homeostasis. Further experimental studies should examine if our findings translate to altered levels of transcription, pathophysiological processes, clinical features, and treatment response to lithium among patients with AD and BIP.
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